The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial

Inclusion Criteria:

1. Ischemic cerebral infarction or TIA within 90 days.

2. Aged above 40 years old.

3. Cranial CT or MRI scan exclude intracranial hemorrhagic diseases

4. Stable clinical and neurological conditions.

5. Informed consent is obtained.

Exclusion Criteria:

1. Intracranial hemorrhage

2. Stroke of other unkonwn causes, or other known causes, such as Takayasu arteritis,Moyamoya disease, dissecting aneurysm and hypercoagulable state, carotidendarterectomy, angiogram, or cardiac surgery

3. Cardio embolism

4. Patients with anticoagulants treament including heparin or warfarin

5. Severe co-morbid or unstable medical condition, ie, heart failure, respiratory failureand renal failure, severe liver dysfunction, malignancy with likelihood of deathwithin the next 2 years

6. Significant memory or behavioural disorder, ie, Alzheimer disease, etc, daily careneeded.

7. A Modified Rankin score is more than 4

8. Abnormal liver function: ALT or AST level ＞1.5 times upper limit of normal; Abnormalrenal function: serum creatinine level ＞2.0mg/dl or 177umol/l:

9. Concurrent participation in another clinical trial

10. Uncontrolled hypertension : systolic blood pressure greater than 180mmHg, or diastolicblood pressure greater than 100mmHg

11. Haemostatic disorder or thrombocytopenia (i.e., PLT＜100×109/l).

12. Currently active peptic ulcer disease

13. Pregnant or breast feeding

14. Planned for major surgery, carotid endarterectomy, or carotid angioplasty

15. Unable to give informed consent.